JP2019523302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523302A5 JP2019523302A5 JP2019526209A JP2019526209A JP2019523302A5 JP 2019523302 A5 JP2019523302 A5 JP 2019523302A5 JP 2019526209 A JP2019526209 A JP 2019526209A JP 2019526209 A JP2019526209 A JP 2019526209A JP 2019523302 A5 JP2019523302 A5 JP 2019523302A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- pharmaceutical composition
- composition
- seq
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091033409 CRISPR Proteins 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 101001029057 Homo sapiens ATP-binding cassette sub-family C member 11 Proteins 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 31
- 230000001225 therapeutic effect Effects 0.000 claims 30
- 239000003814 drug Substances 0.000 claims 17
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- 108020004459 Small interfering RNA Proteins 0.000 claims 9
- 239000004055 small Interfering RNA Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 5
- 101150110927 ABCC11 gene Proteins 0.000 claims 4
- 108700011259 MicroRNAs Proteins 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 150000003384 small molecules Chemical group 0.000 claims 3
- 238000010354 CRISPR gene editing Methods 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 2
- 238000007385 chemical modification Methods 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 210000004392 genitalia Anatomy 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003213 antiperspirant Substances 0.000 claims 1
- 210000002210 apocrine cell Anatomy 0.000 claims 1
- 238000003491 array Methods 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
- 102100037129 ATP-binding cassette sub-family C member 11 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022127495A JP2022169627A (ja) | 2016-07-29 | 2022-08-10 | 腋臭を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368896P | 2016-07-29 | 2016-07-29 | |
| US62/368,896 | 2016-07-29 | ||
| PCT/US2017/044731 WO2018023126A1 (en) | 2016-07-29 | 2017-07-31 | Methods of treating osmidrosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127495A Division JP2022169627A (ja) | 2016-07-29 | 2022-08-10 | 腋臭を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019523302A JP2019523302A (ja) | 2019-08-22 |
| JP2019523302A5 true JP2019523302A5 (enExample) | 2020-09-17 |
Family
ID=61016798
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526209A Pending JP2019523302A (ja) | 2016-07-29 | 2017-07-31 | 腋臭を治療する方法 |
| JP2022127495A Pending JP2022169627A (ja) | 2016-07-29 | 2022-08-10 | 腋臭を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127495A Pending JP2022169627A (ja) | 2016-07-29 | 2022-08-10 | 腋臭を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20210301289A1 (enExample) |
| EP (1) | EP3491129A4 (enExample) |
| JP (2) | JP2019523302A (enExample) |
| KR (1) | KR20190123256A (enExample) |
| WO (1) | WO2018023126A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202104838SA (en) * | 2018-12-03 | 2021-06-29 | Eirion Therapeutics Inc | Improved delivery of large agents |
| CN110124042A (zh) * | 2019-05-28 | 2019-08-16 | 赵叶莲 | 不含铝的抑制腋臭的组合物 |
| JP7440934B2 (ja) * | 2019-08-21 | 2024-02-29 | 国立大学法人 東京大学 | Ａｂｃｃ１１阻害剤 |
| WO2021257630A2 (en) * | 2020-06-15 | 2021-12-23 | Cutler Richelle | Drugs and methods for reducing body odor and sweat |
| WO2024104663A1 (en) | 2022-11-16 | 2024-05-23 | Unilever Ip Holdings B.V. | Method of reducing malodour |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| JP5128273B2 (ja) * | 2004-04-27 | 2013-01-23 | ガラパゴス・ナムローゼ・フェンノートシャップ | 未分化哺乳動物細胞の分化を骨芽細胞へと誘導するための方法、作用物質、及び化合物スクリーニングアッセイ |
| US20120150023A1 (en) * | 2007-08-06 | 2012-06-14 | Kaspar Roger L | Microneedle arrays for active agent delivery |
| EP2667854B1 (en) * | 2011-01-24 | 2019-01-16 | Anterios, Inc. | Nanoparticle compositions |
| AU2012296405B2 (en) * | 2011-08-16 | 2016-03-17 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of breast cancer |
| WO2016094732A1 (en) * | 2014-12-10 | 2016-06-16 | Transderm, Inc. | METHODS OF TREATING PAIN AND/OR ITCH WITH SMALL MOLECULE INHIBITORS TARGETING AN mTOR PATHWAY |
-
2017
- 2017-07-31 EP EP17835426.2A patent/EP3491129A4/en not_active Withdrawn
- 2017-07-31 WO PCT/US2017/044731 patent/WO2018023126A1/en not_active Ceased
- 2017-07-31 JP JP2019526209A patent/JP2019523302A/ja active Pending
- 2017-07-31 US US16/321,583 patent/US20210301289A1/en not_active Abandoned
- 2017-07-31 KR KR1020197005466A patent/KR20190123256A/ko not_active Ceased
-
2022
- 2022-08-10 JP JP2022127495A patent/JP2022169627A/ja active Pending
-
2023
- 2023-04-06 US US18/131,509 patent/US20240167028A1/en not_active Abandoned
-
2024
- 2024-11-25 US US18/959,170 patent/US20250188461A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114681621B (zh) | 肽寡核苷酸缀合物 | |
| DK2694652T3 (en) | MEDICINE FOR LIVER REGENERATION AND FOR THE TREATMENT OF LIVER FAILURE | |
| Simonson et al. | MicroRNA therapeutics: the next magic bullet? | |
| Ling | Non-coding RNAs: therapeutic strategies and delivery systems | |
| JP2019523302A5 (enExample) | ||
| US20160046931A1 (en) | Methods for enhancing utrophin production via inhibition of microrna | |
| JP6944942B2 (ja) | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 | |
| JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
| JP2018531600A5 (enExample) | ||
| JP2015523855A (ja) | Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法 | |
| JP2016502858A5 (enExample) | ||
| JP2020186249A (ja) | 心疾患の処置のための組成物及び方法 | |
| ES3001019T3 (es) | Inhibidores del MICRO-RNA 22 | |
| Pradeep et al. | Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics | |
| JP2022169627A5 (enExample) | ||
| WO2023051822A1 (zh) | 用于治疗与pcsk9相关疾病的靶向寡核苷酸 | |
| JP2021500016A5 (enExample) | ||
| JP7553036B2 (ja) | ｓｎｏＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| CN107922947A (zh) | 用于治疗肌萎缩性侧索硬化症(als)的mir‑155抑制剂 | |
| CN114585633A (zh) | 寡核苷酸缀合物组合物和使用方法 | |
| KR20220104118A (ko) | 핵산 복합체를 함유하는 피부 투과성 전달체 및 이의 용도 | |
| CN104024413B (zh) | 小干扰RNA及其应用和抑制plk1基因表达的方法 | |
| US20180055869A1 (en) | Compositions and methods for modulating rna | |
| CN118109468A (zh) | 诱导外显子50的跳读的反义核酸 | |
| Suryawanshi et al. | A simple alternative to stereotactic injection for brain specific knockdown of miRNA |